IFF Launches SENSORA™, an Innovative Pro-Fragrance Technology Platform

30.6.2026 14:00:00 CEST | Business Wire | Press release

A light-activated fragrance experience enhancer, starting with liquid detergents

IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients and health and biosciences — today announced the launch of SENSORA™, its advanced patent-pending pro-fragrance technology designed to transform how scent is experienced across home, fabric and personal care applications. Developed to meet the rising demand for a longer-lasting and more sophisticated scent experience, SENSORA™ delivers an evolving olfactive profile with sustained release, extending enjoyment well beyond first use.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629247253/en/

SENSORA™, IFF’s light-activated pro-fragrance experience enhancer

“With SENSORA™, we are advancing fragrance performance into a new territory — one where scent continues to reveal itself in real life, long after the first moment of use,” said Ana Paula Mendonça, president of IFF Scent. “By combining pro-fragrance science with our deep expertise in fragrance design, we are creating more enduring, more meaningful experiences that bring consumers joy.”

Where pro-fragrance science meets fragrance experience enhancement

A pro-fragrance is a delivery system designed for the controlled release of scent. At the core of SENSORA™ is an innovative pro-fragrance mechanism engineered to unlock complex olfactive dimensions over time. This activation is triggered by light — both indoor and outdoor — enabling a controlled, phased release of scent from storage through wear.

SENSORA™ is designed to:

Sustain fragrance presence well beyond washing and into use
Reveal new olfactive facets over time, enhancing richness and sophistication
Extend scent perception for days — up to 20 days after activation

First application: fabric care

Today, IFF introduces Floral Fusion under the SENSORA™ platform — its first light-activated pro-fragrance specifically designed for liquid detergents — as part of its fragrance experience enhancer portfolio. It delivers a long-lasting, evolving scent experience, releasing refined floral notes on dry fabrics, enriching the fragrance experience beyond the original scent signature.

“SENSORA™ gives our customers a powerful new way to differentiate in laundry care, a category where consumers increasingly expect fragrance to deliver both lasting impact and elevated sensorial pleasure,” said Jan Bechtel, senior vice president of consumer fragrance for IFF Scent. “Starting with liquid detergents, this breakthrough offering creates new opportunities to build memorable product experiences, strengthen brand preference and respond to evolving consumer expectations.”

Meeting a clear consumer shift

An IFF global usage and attitudes survey conducted in 17 countries in 2026 found that consumers are increasingly seeking benefits that go beyond freshness to deliver lasting impact and sensorial pleasure:

More than one-third expect laundry fragrance to last longer
Nearly one in four want scent to remain noticeable for at least four days

SENSORA™ responds directly to these expectations, delivering premium scent performance designed for real-life conditions.

A scalable platform for future innovation

Part of IFF’s SCENT+™ innovation pillar and grounded in its Science of Performance, SENSORA™ integrates seamlessly into fragrance compositions, giving perfumers precise control to design bespoke performance profiles.

“SENSORA™ represents a step-change in how we design fragrance performance,” said Mohammed Ashour, vice president of innovation for IFF Scent. “Its light-activated pro-fragrance mechanism gives perfumers a new level of control to orchestrate how scent evolves, revealing new olfactive facets over time while providing a scalable platform for innovation across applications and categories.”

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260629247253/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release

IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by

90% of IT Leaders See Gaps in AI Threat Readiness, Lenovo Brings Single Point of Accountability to Cyber Resiliency30.6.2026 15:00:00 CEST | Press release

New end-to-end resilience and managed security offerings help organizations reduce security complexity, cut system downtime by up to 50%, and lower remediation costs by up to 40% by bringing devices, security technologies, expert services, and ecosystem partners together under a single operational model As organizations accelerate AI adoption and digital workplace transformation, many are finding that cyber resilience is undermined not by a lack of security tools, but by growing operational complexity and threat sophistication. According to recent research, 90% of IT leaders acknowledge gaps in their ability to defend against AI-driven threats. While security investments continue to grow, many organizations face a different challenge: fragmented accountability. Security operations remain highly distributed and siloed, making it increasingly difficult to coordinate response efforts, maintain end-to-end business continuity, and recover quickly when incidents occur. To help organizations

Tacton Launches Portfolio Performance Intelligence to Help Manufacturers Understand Why Products Win30.6.2026 15:00:00 CEST | Press release

New configuration-aware commercial intelligence capability connects customer requirements, configuration decisions, and business outcomes to optimize win rates, margin and product strategy. Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the launch of Portfolio Performance Intelligence, a new analytics capability designed to help manufacturers understand why products win, where margin is created or lost, and which decisions consistently drive successful business outcomes. Manufacturers don't lack data. They lack the context needed to understand why products perform the way they do and why customers choose them. ERP systems show what was sold, CRM platforms track opportunities, and BI tools visualize trends. But when manufacturers try to understand which customer requirements drive demand, which configurations consistently win, or why margins vary across products, regions or segments, the answers are often unclear

SC Therapeutics Initiates REACH2 Trial for Refractory Chronic Cough30.6.2026 15:00:00 CEST | Press release

First-in-class disease-modifying therapeutic aerosol targeting mechano-sensitive ion channels advances into phase 2 clinical evaluation in UK SC Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies that deactivate mechano-sensitive ion channels (MSCs) to treat respiratory and cardiovascular disease, today reports initiation of the REACH2 trial. The study will evaluate the Company's lead product candidate in patients with refractory chronic cough (RCC) – a debilitating condition for which no disease-modifying treatment options currently exist. The trial will be run in three major cough centers across the UK. A Novel, Disease-Modifying Mechanism of Action SC0032, SC Therapeutics' most advanced product candidate, is a proprietary therapeutic aerosol composed entirely of ions endogenous to human airways. Unlike current symptomatic investigational drugs – including P2X3 receptor antagonists and neurokinin-1 (NK1) receptor antagonists that seek to dampen neural hyper

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom